INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo CHOLERA VACCINE

CHOLERA VACCINE
Cho/Vac
PROPRIETARY NAME:
CHOLERA VACCINE

DESCRIPTIVE NAME:
A Bacterial Cholera Prophylactic Vaccine

REGISTRATION NUMBER:
T537 (Act 101/1965)

PHARMACOLOGICAL CLASSIFICATION:
A30.1 Antigens

SCHEDULING STATUS:
S2

COMPOSITION:
A suspension in a phosphate buffered saline solution of equal parts of cholera vibrios of serotypes INABA and OGAWA to give 8000 million per 1 mL dose with 0,05% phenol as preservative.

IDENTIFICATION:
A pale milky translucent suspension with a slight odour due to the preservative.

PHARMACOLOGICAL ACTION:
Induces in the recipient a specific immunity to cholera.

INDICATIONS:
For active immunisation against cholera.

CONTRA-INDICATIONS:
Not recommended for patients with an acute infections or for children less than one year old. Should be used with great caution if there has been a history of allergy to previous vaccination.

DOSAGE AND DIRECTIONS FOR USE:
For primary immunisation of adults or children of 14 years or older, two (2) doses of 1 mL are given by subcutaneous injection 14 days apart. It may be expected to confer immunity in about 50% of subjects for up to six months, but persons at risk should be aware of the importance of good hygiene and safe drinking water in the prevention of cholera. The dose for children over 1 year old should be between 0,1 mL and 1 mL in proportion to body mass. Further doses may be given at 6 monthly intervals if required. Not recommended for children less than 1 year old. Sterilise the rubber closure with tincture of iodine and shake vial vigorously before use.

N.B. The immunogenic activity of Cholera is reduced if given within three weeks of a yellow fever injection.

SIDE EFFECTS AND SPECIAL PRECAUTIONS:
Enquiry regarding previous hypersensitivity should precede the administration of a vaccine, and measures to treat reactions should be immediately available. Anaphylactic reactions, which are rare, should be treated with adrenaline, possibly in association with antihistamine and corticosteroid therapy.

Reactions following administration may include anorexia, fever, vomiting, and malaise. May cause transient local and general reactions for which symptomatic treatment should be given. Neurological or psychiatric reactions have occasionally occurred as have the occasional slight swelling, erythema and tenderness at the injection site.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
No known symptoms

PRESENTATION:
Multidose 10 mL vials (10 doses) packed singly.
Multidose 10 mL vials packed 10 x 10 mL.

STORAGE INSTRUCTIONS:
Store at 2° C to 10° C. DO NOT FREEZE. Protect from light.

NAME AND BUSINESS ADDRESS OF APPLICANT:
The South African Institute for Medical Research.
Rietfontein, Edenvale, Transvaal.
P.O. Box 28999, Sandringham, 2131

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
June 1990

102-1292

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996,1997,1998